Literature DB >> 7768769

The utilisation and economic evaluation of antibiotics prescribed in primary care.

T M MacDonald1, D Collins, M M McGilchrist, J Stevens, A D McKendrick, D G McDevitt, P G Davey.   

Abstract

This was an observational study of efficacy and resource utilisation over three years in a cohort of 917 patients who received at least one prescription for an oral antibiotic between January and March 1989 in a large rural primary care health centre in Tayside, Scotland. Three thousand, six hundred and sixty three prescriptions were issued (2286 to females) for; 1502 upper respiratory tract infections, 419 lower respiratory tract infections, 441 urinary tract infections, 177 skin and soft tissue infections, 97 gynaecological infections, 103 cases of acne and 71 other infections. Excluding acne, 14% of infections required more than one antibiotic to achieve a successful outcome. The highest success rates for antibiotics were amoxycillin (92%) and penicillin V (92%) in upper respiratory tract infections, erythromycin (90%) in lower respiratory tract infections and co-trimoxazole (83%) in urinary tract infections. The most cost-effective antibiotics were penicillin V for upper respiratory tract infection, erythromycin for lower respiratory tract infection and co-trimoxazole for urinary tract infection. Varying the value placed on general practitioners' time did not change the rank order of antibiotic cost-effectiveness. The efficacy and cost-effectiveness of the treatment of acute infections in primary care varies considerably with the antibiotic used as first choice. More expensive antibiotics might be justified in cost-effectiveness terms if they had high cure rates in clinical practice.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7768769     DOI: 10.1093/jac/35.1.191

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  5 in total

1.  Modification of general practitioner prescribing of antibiotics by use of a therapeutics adviser (academic detailer).

Authors:  K F Ilett; S Johnson; G Greenhill; L Mullen; J Brockis; C L Golledge; D B Reid
Journal:  Br J Clin Pharmacol       Date:  2000-02       Impact factor: 4.335

Review 2.  Record-linkage for pharmacovigilance in Scotland.

Authors:  J M Evans; T M MacDonald
Journal:  Br J Clin Pharmacol       Date:  1999-01       Impact factor: 4.335

Review 3.  Treatment of urinary tract infection. Clinical and economic considerations.

Authors:  R J Plumridge; C L Golledge
Journal:  Pharmacoeconomics       Date:  1996-04       Impact factor: 4.981

4.  Pharmacoeconomics: a challenge for clinical pharmacologists.

Authors:  T Walley; P Davey
Journal:  Br J Clin Pharmacol       Date:  1995-09       Impact factor: 4.335

5.  Not so simple cystitis: how should prescribers be supported to make informed decisions about the increasing prevalence of infections caused by drug-resistant bacteria?

Authors:  P Davey; D Steinke; T MacDonald; G Phillips; F Sullivan
Journal:  Br J Gen Pract       Date:  2000-02       Impact factor: 5.386

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.